Selective BRAF inhibitors (dabrafenib, vemurafenib, encorafenib) and MEK inhibitors (trametinib, cobimetinib, binimetinib) have demonstrated robust clinical activity, particularly in melanoma, non-small cell lung carcinoma (NSCLC), and colorectal carcinoma harboring MAPK pathway alterations [54]. This evidence concerns the gene MAP2K7 and non-small cell lung carcinoma.